A diabetic woman almost died from the “world’s most dangerous eating disorder” after doctors mistook her insulin misuse for ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

The German Diabetes Society (DDG) issued a warning concerning a rise in pregnancies among women using injectable medications ...

From life-changing medical advancements to colorful auroras, this year has been packed with incredible science. It was hard ...

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...

Sol-Millennium® Medical Group, a leading manufacturer of medical devices, has launched an innovative needle-free injection ...

Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.